NewsRoom Articles - Page 117 of 214

TuesdayApr 05, 2022 9:00 am

Cybin Inc. (NEO: CYBN) (NYSE American: CYBN) Begins Recruitment for Study Measuring Ketamine’s Psychedelic Effect

Cybin-sponsored study will use Kernel Flow, Kernel’s quantitative neuroimaging. Company hopes to learn more about impact ketamine has on brain activity, overall mental well-being. Study results may lead to future studies supporting CYBN’s mission to develop psychedelics into therapeutics. Cybin’s (NEO: CYBN) (NYSE American: CYBN) efforts to transform the mental-health treatment landscape have reached a key milestone: the company is actively recruiting participants for its upcoming feasibility study using Kernel Flow, Kernel’s quantitative neuroimaging technology (https://ibn.fm/9aSxc). “The feasibility study using Kernel Flow offers an opportunity for researchers and our study participants to quantifiably gather information on a psychedelic experience,” said Cybin…

TuesdayApr 05, 2022 9:00 am

Mydecine Innovations Group Inc. (NEO: MYCO) (OTC: MYCOF) (FSE: 0NFA) Leveraging Growth Across Multiple Markets Including Mental Health, Healthcare IT

Mydecine was founded in 2020 as a response to the lack of innovation addressing mental health treatment and the therapeutic possibilities represented by psychedelic compounds and other novel molecules The world is experiencing a shortage of mental health resources, while faced with an increase in mental health issues on the heels of the pandemic Mydecine is leveraging the psychedelic drugs market, the PTSD market, and healthcare IT markets – with potential growth across all avenues In the first year of the COVID-19 pandemic, the prevalence of anxiety and depression worldwide increased by 25%, according to a World Health Organization (“WHO”)…

MondayApr 04, 2022 10:54 am

Reddit Analysis Finds Similarities Between Nonsuicidal Self-Harm Experiences, Addiction

New research has found that the experiences of people who talked about and reported nonsuicidal self-injury on Reddit are similar to individuals who have been diagnosed with substance use disorder. Individuals who posted on a self-injury forum titled r/self-harm in 2010–2019 cited an increase in tolerance or severity and often referred to their activities as an addiction. These are terms that are regularly used by individuals recovering from substance use disorders. Figures estimate that about 7% of adults, 12% of young adults and 17% of adolescents report a history of nonsuicidal self-injury. Currently, there exists no standard approach for the…

MondayApr 04, 2022 9:15 am

CNS Pharmaceuticals, Inc. (NASDAQ: CNSP) CEO John Climaco Shares Company Highlights, Goals at 2022 Virtual Growth Conference Presented by Maxim Group LLC

The three-day event showcased CNS through corporate presentation, fireside chat, and live question and answer sessions CNS has been granted both Orphan Drug Designation and Fast Track status from the FDA for Berubicin in 2020 and 2021, respectively CNS initiated a potentially pivotal global trial of Berubicin for recurrent Glioblastoma Multiforme (“GBM”) with the dosing of the first patients in the trial during 3Q 2021 At the end of 2021, CNS gained approval from swissethics to initiate trial sites in Switzerland for the global trial of Berubicin Virtual event participation can be found on the CNS website under “Events” CNS…

FridayApr 01, 2022 2:39 pm

Timing of Food Intake Impacts Mental Health, Study Says

New research has discovered that the time at which an individual consumes food may impact their mental health. Focusing on what you eat is important for your overall health, but did you know that paying some attention to when you eat may also be good for your mental health? Research has found that abnormal eating times may contribute to poor mental health, including anxiety and depression, as well as weight gain and cardio-metabolic illnesses. Researchers believe that the circadian clock, which aligns the internal processes in our body at optimal times during the day based on environmental cues such as…

ThursdayMar 31, 2022 3:05 pm

Study Finds That Younger Pediatric Brain Cancer Patients Have Poorer Outcomes Than Older Patients

A new study has found that children with brain tumors, particularly those who are three months and younger, have a significantly lower rate of survival in comparison to those aged between 1 and 19. The study was carried out by researchers at the University of Colorado Cancer Center, led by associate professor of pediatric hematology/oncology Adam Green. The researchers reported their findings in the “Journal of Neuro-Oncology.” For their study, the researchers obtained data from more than 14,000 children, aged 19 years and younger, who had been diagnosed with brain tumors; the information came from the Surveillance, Epidemiology and End…

ThursdayMar 31, 2022 9:00 am

CNS Pharmaceuticals, Inc. (NASDAQ: CNSP) Reiterates Commitment to Operational Excellence, Advancing Berubicin Recognition

In a video message to shareholders, CEO John Climaco detailed the operational and clinical progress made by lead drug candidate Berubicin despite market volatility and share price fluctuations CNS is currently enrolling patients into a potentially pivotal global drug trial of Berubicin for recurrent glioblastoma multiforme Interim analysis of the trial is currently expected as early as the first quarter of 2023, once 30-50% of trial patients have been on the study for six months CNS Pharmaceuticals (NASDAQ: CNSP), a clinical-stage biotech company specializing in developing novel treatments for primary and metastatic cancers of the brain and central nervous system,…

WednesdayMar 30, 2022 1:55 pm

Monitoring Glucose Levels May Help Manage Weight

Managing one’s weight may be a bit difficult, especially when it comes to consistency. However, did you know that continuous glucose monitoring (CGM) technology can help? CGM is usually used by individuals with diabetes to help manage and monitor their blood sugar. However, the demand for personalized nutrition has seen continuous glucose monitoring devices being used outside the diabetes space. For instance, companies such as NutriSense promote their CGM product as an overall health solution for everything, including weight loss. NutriSense is focused on improving metabolic health. The company leverages its advanced continuous glucose monitoring technology to personalize individual nutrition.…

WednesdayMar 30, 2022 9:00 am

Silo Pharma Inc. (SILO) Is ‘One to Watch’

Silo recently extended its option with the University of Maryland, Baltimore to explore arthritogenic joint-homing peptides and their use in arthritis-inflamed joints In December 2021, the company announced the issuance of a patent relating to its University of Maryland, Baltimore licensed homing peptide for enhanced targeting of therapeutic agents to the central nervous system The company signed an agreement with Columbia University granting it an option to license certain assets currently under development, including an Alzheimer’s disease formulation targeting NDMARs and 5-HT4Rs, as well as a prophylactic treatment for stress-induced disorders and PTSD Silo currently has under review four U.S.…

TuesdayMar 29, 2022 1:48 pm

Study Finds That Patients with PTSD, Bipolar Disorder May Benefit from Telehealth Treatment

Research has found that a virtual connection to a psychiatrist may help people living in rural communities and grappling with bipolar disorder and post-traumatic stress disorder acquire effective care. The randomized study, which was carried out before the coronavirus pandemic, examined how patients’ clinical characteristics impacted their experience with telehealth as well as how well they observed their treatment course. For their study, the researchers analyzed data from about 1,000 participants with bipolar disorder, post-traumatic stress disorder or both, from 24 clinics in Arkansas, Washington and Michigan. The data was obtained from the Study to Promote Innovation in Rural Integrated…

News and publishing service for medical and biotechnology related companies

Contact us: 512.354.7000

Cybin Inc. (NEO: CYBN) (NYSE American: CYBN) Begins Recruitment for Study Measuring Ketamine’s Psychedelic Effect

Mydecine Innovations Group Inc. (NEO: MYCO) (OTC: MYCOF) (FSE: 0NFA) Leveraging Growth Across Multiple Markets Including Mental Health, Healthcare IT

Reddit Analysis Finds Similarities Between Nonsuicidal Self-Harm Experiences, Addiction

CNS Pharmaceuticals, Inc. (NASDAQ: CNSP) CEO John Climaco Shares Company Highlights, Goals at 2022 Virtual Growth Conference Presented by Maxim Group LLC

Timing of Food Intake Impacts Mental Health, Study Says

Study Finds That Younger Pediatric Brain Cancer Patients Have Poorer Outcomes Than Older Patients

CNS Pharmaceuticals, Inc. (NASDAQ: CNSP) Reiterates Commitment to Operational Excellence, Advancing Berubicin Recognition

Monitoring Glucose Levels May Help Manage Weight

Silo Pharma Inc. (SILO) Is ‘One to Watch’

Study Finds That Patients with PTSD, Bipolar Disorder May Benefit from Telehealth Treatment

Official NewsWire Relationships

BioMedWire Currently Accepts

BioMedWire

Company Search

Site Search